



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/169637/2019

European Medicines Agency decision P/0107/2019

of 22 March 2019

on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMA-001664-PIP02-15-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



European Medicines Agency decision

P/0107/2019

of 22 March 2019

on the acceptance of a modification of an agreed paediatric investigation plan for erenumab (Aimovig), (EMA-001664-PIP02-15-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0370/2016 issued on 4 January 2017, the decision P/0310/2017 issued on 31 October 2017 and the decision P/0068/2018 issued on 16 March 2018,

Having regard to the application submitted by Novartis Europharm Limited on 25 October 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 February 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for erenumab (Aimovig), solution for injection, subcutaneous use, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, 4 – Dublin, Ireland.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/798067/2018
London, 1 February 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001664-PIP02-15-M03

Scope of the application

Active substance(s):

Erenumab

Invented name:

Aimovig

Condition(s):

Prevention of migraine headaches

Authorised indication(s):

See Annex I

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Intravenous use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 25 October 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0370/2016 issued on 4 January 2017, the decision P/0310/2017 issued on 31 October 2017 and the decision P/0068/2018 issued on 16 March 2018.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 4 December 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Prevention of migraine headaches

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- solution for injection, subcutaneous use, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Prevention of migraine headaches

2.1.1. Indication(s) targeted by the PIP

Prophylaxis of migraine

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	2	Study 1 Development of administration device for paediatric patients Study 2 Deleted with EMEA-001664-PIP02-15-M03.
Non-clinical studies	2	Study 3 Enhanced pre-postnatal development study in the cynomolgus monkey Study 4 Juvenile toxicology study in cynomolgus monkey

Clinical studies	3	<p>Study 6</p> <p>An open-label, multiple-dose, pharmacokinetic, safety and tolerability study of erenumab in paediatric subjects from 6 to less than 18 years of age with migraine (20150125)</p> <p><i>(added in procedure EMEA-001664-PIP02-15-M01)</i></p> <p>Study 5</p> <p>Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of erenumab in paediatric subjects from 6 to less than 18 years old with Episodic Migraine (EM) (20160172)</p> <p>Study 7</p> <p>Randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of erenumab in paediatric subjects from 6 to less than 18 years old with Chronic Migraine (CM)</p> <p><i>(added in procedure EMEA-001664-PIP02-15-M01)</i></p>
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of migraine

Authorised indication(s):

- Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous injection